CpG island methylator phenotype involving chromosome 3P confers an increased risk of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 790-797

  Liu, Zeyi ^a   Li, Wenwen ^a   Lei, Zhe ^a   Zhao, Jun ^b   Chen, Xiao Feng ^c   Liu, Rengyun ^a   Peng, Xiaobei ^a   Wu, Zhi Hao ^d   Chen, Jun ^d   Liu, Hongyu ^d   Zhou, Qing Hua ^d   Zhang, Hong Tao ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c SHANGHAI PULMONARY HOSPITAL   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLU PROTEIN; CHEMOTACTIC FACTOR; DNA MARKER; FRAGILE HISTIDINE TRIAD PROTEIN; HOGG1 PROTEIN; RAR B PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SEMAPHORIN 3B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CELL PROLIFERATION; CHROMOSOME 3P; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME 3; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PROMOTER REGION; RISK; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 3; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PROMOTER REGIONS, GENETIC; RISK;

EID: 77953146788     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d862f5     Document Type: Article

References (42)

1. Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004;90:2157-2166.
2. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med 2005;352:2714-2720.
3. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.
4. Zhong S, Fields CR, Su N, et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007;26:2621-2634.
5. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756.
6. Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118:2600-2608.
7. Zhang HT, Chen XF, Wang MH, et al. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 2004;10:2359-2367.
8. Liu Z, Zhao J, Chen XF, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in nonsmall cell lung cancer. Lung Cancer 2008;62:15-22.
9. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-255.
10. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-67.
11. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-160.
12. Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002;7:451-457.
13. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:7329-7338. (Pubitemid 46095405)
14. Feng Q, Hawes SE, Stern JE, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:645-654.
15. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
16. Marsit CJ, Houseman EA, Christensen BC, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006;66:10621-10629.
17. Suzuki M, Shigematsu H, Iizasa T, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006;106:2200-2207.
18. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004;36:497-501.
19. Russo AL, Thiagalingam A, Pan H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smokeinduced neoplastic progression of lung cancer. Clin Cancer Res 2005;11:2466-2470.
20. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
21. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008;122:952-956.
22. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
23. Youssef EM, Lotan D, Issa JP, et al. Hypermethylation of the retinoic acid receptor-beta (2) gene in head and neck carcinogenesis. Clin Cancer Res 2004;10:1733-1742.
24. Kuroki T, Trapasso F, Yendamuri S, et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res 2003;63:3352-3355.
25. Lo KW, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001;61:3877-3881.
26. Liu XQ, Chen HK, Zhang XS, et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer 2003;106:60-65.
27. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-3585.
28. Oue N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006;106:1250-1259.
29. Ottini L, Falchetti M, Lupi R, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006;17: vii97-vii102.
30. Grunwald C, Koslowski M, Arsiray T, et al. Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer 2006;118:2522-2528.
31. An C, Choi IS, Yao JC, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005;11:656-663.
32. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 2007;6:70.
33. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
34. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
35. Breuer RH, Postmus PE, Smit EF. Molecular pathology of non-smallcell lung cancer. Respiration 2005;72:313-330.
36. Watanabe N, Okochi-Takada E, Yagi Y, et al. Decreased fidelity in replicating DNA methylation patterns in cancer cells leads to dense methylation of a CpG island. Curr Top Microbiol Immunol 2006;310:199-210.
37. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
38. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99:375-382.
39. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-2919.
40. Ogino S, Odze RD, Kawasaki T, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006;30:1175-1183. (Pubitemid 44299351)
41. Zhang C, Li Z, Cheng Y, et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007;13:944-952.
42. Suzuki M, Sunaga N, Shames DS, et al. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004;64:3137-3143.